SOPHiA GENETICS (SOPH) announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS powered with SOPHiA DDM, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca (AZN), SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide over the next 12 months. “Our collaboration with AstraZeneca has the potential to dramatically accelerate global access to liquid biopsy testing, especially in underserved populations, which in turn could contribute to reshaping diagnostics, treatment, and monitoring of cancer cases throughout the world. Their support is instrumental to making this improved access a reality,” said Philippe Menu, M.D., Ph.D, Chief Medical and Chief Product Officer, SOPHiA GENETICS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOPH:
- Sophia Genetics announces CE mark for Sophia DDM Platform under IVDR
- Sophia Genetics downgraded to Equal Weight from Overweight at Morgan Stanley
- SOPHiA GENETICS Reports Mid-Year Financials
- Sophia Genetics cuts FY24 revenue view to $65M-$67M from $78M-$81M
- Sophia Genetics reports Q2 EPS (23c), consensus (28c)